抗マラリア薬市場：薬剤クラス別、薬剤タイプ別、投与経路別、マラリアタイプ別、流通チャネル別、エンドユーザー別-2024～2030年の世界予測

抗マラリア薬市場規模は、2023年に16億7,000万米ドルと推定され、2024年には17億6,000万米ドルに達し、CAGR 5.88％で2030年には25億米ドルに達すると予測されています。

抗マラリア薬は、感染したアノフェレス蚊に刺されることで感染し、生命を脅かす病気であるマラリアの予防と治療を目的とした医薬品化合物です。これらの医薬品は、マラリアの原因であるマラリア原虫の様々なライフサイクルステージを標的とし、マラリアの感染を効果的に減少させ、罹患者の症状を緩和します。抗マラリア薬」の有用性は、流行地域への旅行者における予防的使用から、診断された症例における治療的介入まで、さまざまな状況に及ぶ。これらの薬剤の開発と配備は、特にマラリアの流行が最も高い熱帯・亜熱帯地域において、マラリアの制圧、撲滅、根絶を目指す世界ヘルス活動において極めて重要です。世界のマラリア罹患率の上昇と、マラリア撲滅プログラムに対する世界保健機関からの支援の増加が、抗マラリア薬市場の成長を促進しています。しかし、薬剤耐性マラリア株の出現が抗マラリア薬市場の拡大を妨げています。抗マラリア薬分野の薬剤開発や診断検査における革新は、市場に有利な成長機会を提供します。

薬剤クラス別アルテミシニン化合物の効果的な結果による使用の拡大

ピリメタミンやスルファドキシンなどの抗葉酸化合物は、マラリア原虫の核酸やタンパク質の生産に不可欠な、マラリア原虫内での葉酸合成を阻害することで効果を発揮します。これらの化合物は、有効性を高め、耐性を防止するために、しばしば併用されます。アルテミシニンをベースとする併用療法（ACT）は、現代のマラリア治療の基礎であり、世界のマラリア死亡率の減少に大きく貢献しています。アルテミシニンおよびその誘導体であるアルテスネート、アルテメーテル、ジヒドロアルテミシニンは、植物アルテミシアから誘導され、マラリア原虫に対して即効性があり、非常に有効です。アリールアミノアルコール化合物には、キニーネ、メフロキン、ハロファントリンなどがあり、これらは主に原虫の赤血球期に有効です。長い間使用されてきたにもかかわらず、耐性菌の発生や副作用のため、新しい薬剤に取って代わられ、その使用は制限されてきました。エンドペルオキシドは特定の状況、特に多剤耐性マラリア株の治療には不可欠です。エンドペルオキシドは、アルテミシニン耐性と闘うために開発された新しい薬剤です。オゾニドOZ439（artefenomel）のようなこれらの化合物は、抗マラリア活性に必要な重要な過酸化物ブリッジを保持しており、臨床試験が進行中の抗マラリア治療法として有望な未来を提供しています。メフロキンやルメファントリンを含むキノリン・メタノール系抗マラリア薬は、薬剤耐性P. falciparumに対して有効です。これらの抗マラリア薬の作用機序には、寄生虫内のヘモグロビン消化を阻害することが含まれます。ドキシサイクリンなどのテトラサイクリン系抗生物質は、マラリアに対する併用療法の一環として、特に薬剤耐性の寄生虫がいる地域での治療や予防に用いられる広域スペクトル抗生物質です。その安全性と費用対効果から、テトラサイクリン系抗菌薬は特定の治療場面で安定的に使用され続けています。

マラリアの種類：マラリア原虫の増加

マラリア原虫はマラリア原虫の中でも危険な寄生虫で、しばしば重症マラリアにつながります。このタイプのマラリアは病原性が高く、進行が速いため、治療には即効性のある抗マラリア薬が必要です。アルテミシニンを主成分とする混合療法（ACT）は、世界中でP. falciparumマラリアの治療薬として推奨されています。これにはアルテメーテル-ルメファントリンやアルテスネート-アモジアキンなどの組み合わせが含まれます。ACTに耐性のある地域では、キニーネにドキシサイクリンやクリンダマイシンを加えたレジメンが使用されることもあります。重症マラリア症例にはアルテスネートの静脈内投与が望ましいです。当初はサルに感染することで知られていたPlasmodium knowlesiは、東南アジアでヒトマラリアの重要な原因として出現しました。このマラリア原虫はライフサイクルが早く、重症マラリアに至る可能性があるため、治療戦略はマラリア原虫と同様です。アルテミシニンベースの併用療法（ACT）が有効です。マラリア原虫は、一般的にマラリア原虫よりも重症度が低いです。マラリア原虫の治療には通常クロロキンが十分です。クロロキン耐性が懸念されない場合は、その有効性と低コストのため、この薬剤が第一選択です。ovaleマラリア原虫は、P. vivaxと同様に休眠肝ステージによる再発性マラリアを引き起こします。オバレ原虫の治療には、血液期の感染にはクロロキンを、休眠肝期を除去して再発を防ぐにはプリマキンを使用します。この2つのアプローチにより、血流と肝臓から寄生虫を確実に除去し、再発を防ぎます。熱帯熱マラリア原虫は、肝臓の休眠期（hypnozoites）によりマラリアの再発を引き起こすことが知られています。治療には、血液期の感染にはクロロキンを、肝臓期の感染にはプリマキンを使用します。新たな代替薬であるタフェノキンは、プリマキンと同様の効果をもたらすが、G6PD欠乏症のスクリーニングが必要です。

地域別インサイト

南北アメリカでは、ブラジル、コロンビア、ペルーなどの南米や、中米、カリブ海諸国の一部など、マラリア患者が後を絶たない国を中心に抗マラリア薬が注目されています。市場力学の特徴は、マラリア撲滅のための取り組みや資金提供など、政府の積極的な介入です。アジア太平洋地域は、インド、中国、インドネシアなど国によってマラリアの流行状況や医療インフラが異なるため、非常に多様な抗マラリア薬市場となっています。リスクの高い人口の多さ、蚊の繁殖を助長する気候条件、社会経済格差などの要因が市場に影響を与えています。マラリア撲滅・制圧に向けた取り組みは強化されており、政府や国際機関によるヘルスケアシステムへの多額の投資が抗マラリア薬の需要を押し上げています。偽造薬や薬剤耐性の問題は依然として重大な懸念事項です。欧州では、厳しい規制基準とマラリア予防に対する高い意識が、消費者の購買行動の指針となっています。EUにおける最近の研究開発は、ワクチン開発と新規抗マラリア化合物の発見に重点を置いています。EMEA（欧州・中東・アフリカ）地域は、マラリア患者が多いアフリカと異なる市場特性を示しています。サハラ以南のアフリカにおける抗マラリア薬の需要は、アルテミシニンを主成分とする併用療法（ACT）などの薬剤の普及により、依然として高いです。中東では、流行率にばらつきがあります。特にアフリカにおけるマラリア撲滅・制圧への取り組みが、EMEA地域の抗マラリア薬市場を牽引すると予想されます。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは抗マラリア薬市場を評価する上で極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、抗マラリア薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.抗マラリア薬市場の市場規模および予測は？

2.抗マラリア薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.抗マラリア薬市場の技術動向と規制枠組みは？

4.抗マラリア薬市場における主要ベンダーの市場シェアは？

5.抗マラリア薬市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • マラリアの発生率は世界的に上昇しており、特に熱帯・亜熱帯地域で顕著です。
    • マラリア撲滅プログラムに対する世界保健機関からの支援の増加
  • 抑制要因
    • 薬剤耐性マラリア株の出現
  • 機会
    • 抗マラリア薬の普及促進に向けた政府と製薬会社の協力
    • マラリアに対する医薬品開発および診断検査の研究開発
  • 課題
    • 投薬量の誤り、厳格な遵守、薬剤の品質の低さに関連する問題
• 市場セグメンテーション分析
  • 薬物クラス：アルテミシニン化合物の有効性により使用が拡大
  • マラリアの種類：熱帯マラリア原虫の蔓延が増加
• 市場ディスラプション分析
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 価格分析
• 技術分析
• 特許分析
• 貿易分析
• 規制枠組みの分析

第6章 抗マラリア薬市場薬剤クラス別

• 抗葉酸化合物
• アルテミシニン化合物
• アリールアミノアルコール化合物
• エンドペルオキシド
• キノリンメタノール
• テトラサイクリン

第7章 抗マラリア薬市場薬の種類別

• ブランド
• ジェネリック

第8章 抗マラリア薬市場：投与経路別

• 静脈内
• オーラル

第9章 抗マラリア薬市場マラリアの種類別

• 熱帯熱マラリア原虫
• マラリア原虫
• マラリア原虫
• 卵形マラリア原虫
• 三日熱マラリア原虫

第10章 抗マラリア薬市場：流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第11章 抗マラリア薬市場：エンドユーザー別

• 病院
• 専門クリニック

第12章 南北アメリカの抗マラリア薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第13章 アジア太平洋地域の抗マラリア薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第14章 欧州・中東・アフリカの抗マラリア薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第15章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • ケニアの製薬会社がアフリカで初めてマラリア治療薬としてWHOの承認を取得
  • Fosun PharmaとIFCが提携し、アフリカにおける高品質医薬品へのアクセスを向上
  • Fosun Pharmaが革新的なアルテミシニンベースの抗マラリア薬を開発
• 戦略分析と提言

第16章 競争力のあるポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. ANTIMALARIAL DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. ANTIMALARIAL DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. ANTIMALARIAL DRUGS MARKET DYNAMICS
• FIGURE 7. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2023 VS 2030 (%)
• FIGURE 14. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 16. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 18. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 22. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 23. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 24. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 25. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 26. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 27. ANTIMALARIAL DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 28. ANTIMALARIAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ANTIMALARIAL DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ANTIFOLATE COMPOUNDS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ANTIFOLATE COMPOUNDS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ COMPOUNDS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ COMPOUNDS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARYL AMINOALCOHOL COMPOUNDS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARYL AMINOALCOHOL COMPOUNDS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ENDOPEROXIDES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ENDOPEROXIDES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY QUINOLINE METHANOLS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY QUINOLINE METHANOLS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2024-2030 (USD MILLION)
• TABLE 35. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY PLASMODIUM FALCIPARUM, BY REGION, 2018-2023 (USD MILLION)
• TABLE 36. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY PLASMODIUM FALCIPARUM, BY REGION, 2024-2030 (USD MILLION)
• TABLE 37. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY PLASMODIUM KNOWLESI, BY REGION, 2018-2023 (USD MILLION)
• TABLE 38. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY PLASMODIUM KNOWLESI, BY REGION, 2024-2030 (USD MILLION)
• TABLE 39. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY PLASMODIUM MALARIAE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 40. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY PLASMODIUM MALARIAE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 41. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY PLASMODIUM OVALE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 42. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY PLASMODIUM OVALE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 43. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY PLASMODIUM VIVAX, BY REGION, 2018-2023 (USD MILLION)
• TABLE 44. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY PLASMODIUM VIVAX, BY REGION, 2024-2030 (USD MILLION)
• TABLE 45. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 46. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 47. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 48. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 49. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 50. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 51. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 52. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 53. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 54. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 55. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 56. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 57. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 58. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 59. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 60. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 61. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 62. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 63. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 64. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 65. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2023 (USD MILLION)
• TABLE 66. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2024-2030 (USD MILLION)
• TABLE 67. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 68. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 69. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 70. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 71. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 72. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 73. ARGENTINA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 74. ARGENTINA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 75. ARGENTINA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 76. ARGENTINA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 77. ARGENTINA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 78. ARGENTINA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 79. ARGENTINA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2023 (USD MILLION)
• TABLE 80. ARGENTINA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2024-2030 (USD MILLION)
• TABLE 81. ARGENTINA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 82. ARGENTINA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 83. ARGENTINA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 84. ARGENTINA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 85. BRAZIL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 86. BRAZIL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 87. BRAZIL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 88. BRAZIL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 89. BRAZIL ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 90. BRAZIL ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 91. BRAZIL ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2023 (USD MILLION)
• TABLE 92. BRAZIL ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2024-2030 (USD MILLION)
• TABLE 93. BRAZIL ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 94. BRAZIL ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 95. BRAZIL ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 96. BRAZIL ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 97. CANADA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 98. CANADA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 99. CANADA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 100. CANADA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 101. CANADA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 102. CANADA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 103. CANADA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2023 (USD MILLION)
• TABLE 104. CANADA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2024-2030 (USD MILLION)
• TABLE 105. CANADA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 106. CANADA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 107. CANADA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 108. CANADA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 109. MEXICO ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 110. MEXICO ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 111. MEXICO ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 112. MEXICO ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 113. MEXICO ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 114. MEXICO ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 115. MEXICO ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2023 (USD MILLION)
• TABLE 116. MEXICO ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2024-2030 (USD MILLION)
• TABLE 117. MEXICO ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 118. MEXICO ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 119. MEXICO ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 120. MEXICO ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 121. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 122. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 123. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 124. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 125. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 126. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 127. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2023 (USD MILLION)
• TABLE 128. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2024-2030 (USD MILLION)
• TABLE 129. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 130. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 131. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 132. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 133. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 134. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 135. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 136. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 137. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 138. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 139. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 140. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 141. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2023 (USD MILLION)
• TABLE 142. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2024-2030 (USD MILLION)
• TABLE 143. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 144. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 145. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 146. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 147. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 148. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 149. AUSTRALIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 150. AUSTRALIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 151. AUSTRALIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 152. AUSTRALIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 153. AUSTRALIA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 154. AUSTRALIA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 155. AUSTRALIA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2023 (USD MILLION)
• TABLE 156. AUSTRALIA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2024-2030 (USD MILLION)
• TABLE 157. AUSTRALIA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 158. AUSTRALIA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 159. AUSTRALIA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 160. AUSTRALIA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 161. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 162. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 163. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 164. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 165. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 166. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 167. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2023 (USD MILLION)
• TABLE 168. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2024-2030 (USD MILLION)
• TABLE 169. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 170. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 171. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 172. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 173. INDIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 174. INDIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 175. INDIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 176. INDIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 177. INDIA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 178. INDIA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 179. INDIA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2023 (USD MILLION)
• TABLE 180. INDIA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2024-2030 (USD MILLION)
• TABLE 181. INDIA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 182. INDIA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 183. INDIA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 184. INDIA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 185. INDONESIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 186. INDONESIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 187. INDONESIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 188. INDONESIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 189. INDONESIA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 190. INDONESIA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 191. INDONESIA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2023 (USD MILLION)
• TABLE 192. INDONESIA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2024-2030 (USD MILLION)
• TABLE 193. INDONESIA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 194. INDONESIA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 195. INDONESIA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 196. INDONESIA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 197. JAPAN ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 198. JAPAN ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 199. JAPAN ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 200. JAPAN ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 201. JAPAN ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 202. JAPAN ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 203. JAPAN ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2023 (USD MILLION)
• TABLE 204. JAPAN ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2024-2030 (USD MILLION)
• TABLE 205. JAPAN ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 206. JAPAN ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 207. JAPAN ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 208. JAPAN ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 209. MALAYSIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 210. MALAYSIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 211. MALAYSIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 212. MALAYSIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 213. MALAYSIA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 214. MALAYSIA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 215. MALAYSIA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2023 (USD MILLION)
• TABLE 216. MALAYSIA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2024-2030 (USD MILLION)
• TABLE 217. MALAYSIA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 218. MALAYSIA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 219. MALAYSIA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 220. MALAYSIA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 221. PHILIPPINES ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 222. PHILIPPINES ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 223. PHILIPPINES ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 224. PHILIPPINES ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 225. PHILIPPINES ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 226. PHILIPPINES ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 227. PHILIPPINES ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2023 (USD MILLION)
• TABLE 228. PHILIPPINES ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2024-2030 (USD MILLION)
• TABLE 229. PHILIPPINES ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 230. PHILIPPINES ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 231. PHILIPPINES ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 232. PHILIPPINES ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 233. SINGAPORE ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 234. SINGAPORE ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 235. SINGAPORE ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 236. SINGAPORE ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 237. SINGAPORE ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 238. SINGAPORE ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 239. SINGAPORE ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2023 (USD MILLION)
• TABLE 240. SINGAPORE ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2024-2030 (USD MILLION)
• TABLE 241. SINGAPORE ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 242. SINGAPORE ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 243. SINGAPORE ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 244. SINGAPORE ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 245. SOUTH KOREA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 246. SOUTH KOREA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 247. SOUTH KOREA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 248. SOUTH KOREA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 249. SOUTH KOREA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 250. SOUTH KOREA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 251. SOUTH KOREA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2023 (USD MILLION)
• TABLE 252. SOUTH KOREA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2024-2030 (USD MILLION)
• TABLE 253. SOUTH KOREA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 254. SOUTH KOREA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 255. SOUTH KOREA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 256. SOUTH KOREA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 257. TAIWAN ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 258. TAIWAN ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 259. TAIWAN ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 260. TAIWAN ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 261. TAIWAN ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 262. TAIWAN ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 263. TAIWAN ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2023 (USD MILLION)
• TABLE 264. TAIWAN ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2024-2030 (USD MILLION)
• TABLE 265. TAIWAN ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 266. TAIWAN ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 267. TAIWAN ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 268. TAIWAN ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 269. THAILAND ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 270. THAILAND ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 271. THAILAND ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 272. THAILAND ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 273. THAILAND ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 274. THAILAND ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 275. THAILAND ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2023 (USD MILLION)
• TABLE 276. THAILAND ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2024-2030 (USD MILLION)
• TABLE 277. THAILAND ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 278. THAILAND ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 279. THAILAND ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 280. THAILAND ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 281. VIETNAM ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 282. VIETNAM ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 283. VIETNAM ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 284. VIETNAM ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 285. VIETNAM ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 286. VIETNAM ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 287. VIETNAM ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2023 (USD MILLION)
• TABLE 288. VIETNAM ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2024-2030 (USD MILLION)
• TABLE 289. VIETNAM ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 290. VIETNAM ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 291. VIETNAM ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 292. VIETNAM ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 293. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 294. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 295. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 296. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 297. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 298. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 299. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2023 (USD MILLION)
• TABLE 300. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2024-2030 (USD MILLION)
• TABLE 301. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 302. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 303. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 304. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 305. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 306. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 307. DENMARK ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 308. DENMARK ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 309. DENMARK ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 310. DENMARK ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 311. DENMARK ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 312. DENMARK ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 313. DENMARK ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2023 (USD MILLION)
• TABLE 314. DENMARK ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2024-2030 (USD MILLION)
• TABLE 315. DENMARK ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 316. DENMARK ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 317. DENMARK ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 318. DENMARK ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 319. EGYPT ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 320. EGYPT ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 321. EGYPT ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 322. EGYPT ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 323. EGYPT ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 324. EGYPT ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 325. EGYPT ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2023 (USD MILLION)
• TABLE 326. EGYPT ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2024-2030 (USD MILLION)
• TABLE 327. EGYPT ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 328. EGYPT ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 329. EGYPT ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 330. EGYPT ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 331. FINLAND ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 332. FINLAND ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 333. FINLAND ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 334. FINLAND ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 335. FINLAND ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 336. FINLAND ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 337. FINLAND ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2023 (USD MILLION)
• TABLE 338. FINLAND ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2024-2030 (USD MILLION)
• TABLE 339. FINLAND ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 340. FINLAND ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 341. FINLAND ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 342. FINLAND ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 343. FRANCE ANTIM

[190 Pages Report] The Antimalarial Drugs Market size was estimated at USD 1.67 billion in 2023 and expected to reach USD 1.76 billion in 2024, at a CAGR 5.88% to reach USD 2.50 billion by 2030.

Antimalarial drugs are pharmaceutical compounds designed to prevent and treat malaria, a life-threatening disease transmitted by an infected Anopheles mosquito bite. These drugs target the different life cycle stages of the Plasmodium parasites responsible for malaria, effectively reducing the disease's transmission and alleviating the symptoms in affected individuals. Antimalarial drugs' utility spans various contexts, from prophylactic usage in travelers to endemic regions to therapeutic interventions in diagnosed cases. The development and deployment of these medications are critical in global health efforts aimed at controlling, eliminating, and eradicating malaria, particularly in tropical and subtropical regions where the disease prevalence is highest. Rising incidence rates of malaria globally and the increasing support from global health organizations for malaria eradication programs are driving the growth of the antimalarial drugs market. However, the emergence of drug-resistant malaria strains is hindering the expanding antimalarial drugs market. Innovations in drug development and diagnostic tests in the area of antimalarial drugs offer lucrative growth opportunities for the market.

Drug Class: Widening use of artemisinin compounds owing to its effective results

Antifolate compounds, such as pyrimethamine and sulfadoxine, work by inhibiting folate synthesis within the malaria parasite, essential for its nucleic acid and protein production. These compounds are often combined to enhance their efficacy and prevent resistance. Artemisinin-based combination therapies (ACTs) are the cornerstone of modern malaria treatment and have significantly contributed to the reduction in malaria mortality rates worldwide. Derived from the plant Artemisia annua, artemisinin and its derivatives, such as artesunate, artemether, and dihydroartemisinin, are fast-acting and highly effective against Plasmodium falciparum. Aryl aminoalcohol compounds include quinine, mefloquine, and halofantrine, which are primarily effective against the erythrocytic stages of Plasmodium parasites. Despite their long history of use, the development of resistance and side effects have limited their use in favor of newer medications. They remain essential in certain contexts, particularly for treating multidrug-resistant strains of malaria. Endoperoxides include new developments designed to combat artemisinin resistance. These compounds, such as ozonide OZ439 (artefenomel), retain the vital peroxide bridge necessary for their antimalarial activity and offer a promising future for antimalarial treatment modalities with ongoing clinical trials. Quinoline methanol antimalarials, including mefloquine and lumefantrine, are effective against drug-resistant P. falciparum. Their mode of action includes interference with hemoglobin digestion within the parasite. Tetracyclines, such as doxycycline, are broad-spectrum antibiotics used as part of combination therapy for malaria, especially for treatment and prevention in areas with drug-resistant parasites. Due to their safety profile and cost-effectiveness, tetracyclines continue to see steady use in specific therapeutic scenarios.

Malaria Type: Increasing prevalence of plasmodium falciparum

Plasmodium falciparum is dangerous among the malaria parasites, often leading to severe malaria. This type of malaria requires fast-acting antimalarial drugs for treatment due to their high virulence and rapid progression. Artemisinin-based combination therapies (ACTs) are the recommended treatment for P. falciparum malaria worldwide. These include combinations such as artemether-lumefantrine and artesunate-amodiaquine. Other regimens, such as quinine combined with doxycycline or clindamycin, may be used in regions resistant to ACTs. Intravenous artesunate is preferred for severe malaria cases. Plasmodium knowlesi, initially known for infecting macaques, has emerged as a significant cause of human malaria in Southeast Asia. The treatment strategy for P. knowlesi is similar to that for Plasmodium falciparum due to its rapid lifecycle potentially leading to severe malaria. Artemisinin-based combination therapy (ACT) is effective. Plasmodium malariae causes a generally less severe form of malaria than P. falciparum. Chloroquine is typically adequate for treating P. malariae infections. Where chloroquine resistance is not a concern, this drug remains the first choice due to its effectiveness and low cost. Plasmodium ovale causes relapsing malaria due to dormant liver stages, similar to P. vivax. The treatment for P. ovale encompasses chloroquine for the blood-stage infection and a course of primaquine to clear the dormant liver stage and prevent relapse. This two-pronged approach ensures the elimination of the parasite from the bloodstream and the liver to prevent recurrence. Plasmodium vivax is notable for its ability to cause relapsing malaria due to dormant stages in the liver (hypnozoites). Treatment involves the use of chloroquine for the blood-stage infection paired with primaquine to eradicate the liver stage. Tafenoquine, a new alternative, offers similar benefits to primaquine but requires less frequent dosing, although it also requires screening for G6PD deficiency.

Regional Insights

In the Americas, the focus on antimalarial drugs predominantly revolves around countries with persistent malaria cases, such as Brazil, Colombia, and Peru in South America and some parts of Central America and the Caribbean. The market dynamics are characterized by active government intervention, including initiatives and funding to eradicate malaria. The Asia-Pacific region represents a highly diverse antimalarial drugs market due to varying malaria prevalence and healthcare infrastructure across countries such as India, China, and Indonesia. Factors such as a large at-risk population, climatic conditions conducive to mosquito breeding, and socio-economic disparities impact the market. Efforts toward malaria elimination and control have been intensified, with significant investments from governments and international bodies in healthcare systems, boosting the demand for antimalarial drugs. Issues of counterfeit drugs and drug resistance remain critical concerns. Stringent regulatory standards and a high level of awareness regarding malaria prevention guide consumer purchasing behavior in Europe. Recent research initiatives in the EU focus on vaccine development and the discovery of new antimalarial compounds. The EMEA region exhibits different market characteristics, with Africa having high malaria cases. The demand for antimalarial drugs in Sub-Saharan Africa remains high, driven by the prevalent use of drugs such as artemisinin-based combination therapies (ACTs). The Middle East experiences varied prevalence rates. The malaria elimination and control initiatives, especially in Africa, are expected to drive the antimalarial drugs market in the EMEA region.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Antimalarial Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antimalarial Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Antimalarial Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alkem Laboratories, Alliance Pharma, Alvizia Health Care, Bayer AG, Cipla Inc., Dr. Reddy's Laboratories, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Glenmark Pharmaceuticals, Hikma Pharmaceuticals PLC, Ipca Laboratories Ltd., Lincoln Pharmaceuticals, Lupin Limited, Merck KGaA, Mylan, Novartis AG, Pfizer Inc., Sanofi Group, Strides Pharma Science Limited, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company, Teva Pharmaceuticals Industries Ltd., Zydus Group, and Zydus Lifesciences Ltd..

Market Segmentation & Coverage

This research report categorizes the Antimalarial Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Drug Class
  • Antifolate compounds
  • Artemisinin compounds
  • Aryl aminoalcohol compounds
  • Endoperoxides
  • Quinoline Methanols
  • Tetracyclines

• Drug Type
  • Branded
  • Generic

• Route of Administration
  • Intravenous
  • Oral

• Malaria Type
  • Plasmodium Falciparum
  • Plasmodium Knowlesi
  • Plasmodium Malariae
  • Plasmodium Ovale
  • Plasmodium Vivax

• Distribution Channel
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

• End User
  • Hospitals
  • Specialty Clinics

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Antimalarial Drugs Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antimalarial Drugs Market?

3. What are the technology trends and regulatory frameworks in the Antimalarial Drugs Market?

4. What is the market share of the leading vendors in the Antimalarial Drugs Market?

5. Which modes and strategic moves are suitable for entering the Antimalarial Drugs Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising incidence rates of malaria globally, particularly in tropical and subtropical regions
    • 5.1.1.2. Increasing support from global health organizations for malaria eradication programs
  • 5.1.2. Restraints
    • 5.1.2.1. Emergence of drug-resistant malaria strains
  • 5.1.3. Opportunities
    • 5.1.3.1. Collaborations between governments and pharmaceutical companies for increasing penetration of anti-malaria drugs
    • 5.1.3.2. Research and development in drug development and diagnostic tests for malaria
  • 5.1.4. Challenges
    • 5.1.4.1. Issues related to incorrect dosing, strict compliance, and poor drug quality
• 5.2. Market Segmentation Analysis
  • 5.2.1. Drug Class: Widening use of artemisinin compounds owing to its effective results
  • 5.2.2. Malaria Type: Increasing prevalence of plasmodium falciparum
• 5.3. Market Disruption Analysis
• 5.4. Porter's Five Forces Analysis
  • 5.4.1. Threat of New Entrants
  • 5.4.2. Threat of Substitutes
  • 5.4.3. Bargaining Power of Customers
  • 5.4.4. Bargaining Power of Suppliers
  • 5.4.5. Industry Rivalry
• 5.5. Value Chain & Critical Path Analysis
• 5.6. Pricing Analysis
• 5.7. Technology Analysis
• 5.8. Patent Analysis
• 5.9. Trade Analysis
• 5.10. Regulatory Framework Analysis

6. Antimalarial Drugs Market, by Drug Class

• 6.1. Introduction
• 6.2. Antifolate compounds
• 6.3. Artemisinin compounds
• 6.4. Aryl aminoalcohol compounds
• 6.5. Endoperoxides
• 6.6. Quinoline Methanols
• 6.7. Tetracyclines

7. Antimalarial Drugs Market, by Drug Type

• 7.1. Introduction
• 7.2. Branded
• 7.3. Generic

8. Antimalarial Drugs Market, by Route of Administration

• 8.1. Introduction
• 8.2. Intravenous
• 8.3. Oral

9. Antimalarial Drugs Market, by Malaria Type

• 9.1. Introduction
• 9.2. Plasmodium Falciparum
• 9.3. Plasmodium Knowlesi
• 9.4. Plasmodium Malariae
• 9.5. Plasmodium Ovale
• 9.6. Plasmodium Vivax

10. Antimalarial Drugs Market, by Distribution Channel

• 10.1. Introduction
• 10.2. Hospital Pharmacies
• 10.3. Online Pharmacies
• 10.4. Retail Pharmacies

11. Antimalarial Drugs Market, by End User

• 11.1. Introduction
• 11.2. Hospitals
• 11.3. Specialty Clinics

12. Americas Antimalarial Drugs Market

• 12.1. Introduction
• 12.2. Argentina
• 12.3. Brazil
• 12.4. Canada
• 12.5. Mexico
• 12.6. United States

13. Asia-Pacific Antimalarial Drugs Market

• 13.1. Introduction
• 13.2. Australia
• 13.3. China
• 13.4. India
• 13.5. Indonesia
• 13.6. Japan
• 13.7. Malaysia
• 13.8. Philippines
• 13.9. Singapore
• 13.10. South Korea
• 13.11. Taiwan
• 13.12. Thailand
• 13.13. Vietnam

14. Europe, Middle East & Africa Antimalarial Drugs Market

• 14.1. Introduction
• 14.2. Denmark
• 14.3. Egypt
• 14.4. Finland
• 14.5. France
• 14.6. Germany
• 14.7. Israel
• 14.8. Italy
• 14.9. Netherlands
• 14.10. Nigeria
• 14.11. Norway
• 14.12. Poland
• 14.13. Qatar
• 14.14. Russia
• 14.15. Saudi Arabia
• 14.16. South Africa
• 14.17. Spain
• 14.18. Sweden
• 14.19. Switzerland
• 14.20. Turkey
• 14.21. United Arab Emirates
• 14.22. United Kingdom

15. Competitive Landscape

• 15.1. Market Share Analysis, 2023
• 15.2. FPNV Positioning Matrix, 2023
• 15.3. Competitive Scenario Analysis
  • 15.3.1. Kenya Manufacturer Is First In Africa to Get WHO Approval For Malaria Drug
  • 15.3.2. Fosun Pharma and IFC Partner to Improve Access to High Quality Medicines in Africa
  • 15.3.3. Fosun Pharma Develops Innovative Artemisinin-based Antimalarial Drugs
• 15.4. Strategy Analysis & Recommendation

16. Competitive Portfolio

• 16.1. Key Company Profiles
• 16.2. Key Product Portfolio